Today I go through the subgroup analyses of BAN2401 from Biogen/Eisai, the latest Esperion p3 data and the disappointing results from Adamas' Q3 results. This is not investment advice, but only for information purposes. Follow me @matthewlepoire www.breakingbiotech.com biib #espr #adms